Every finding on thiamine
18 findings, by evidence strength
18 shown
- All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.37[0.18 to 0.78]Evidence: Moderatereplicated ×9Paper: PMID 341932352021
- Who
- Critically ill adults with COVID-19 in two ICUs, retrospective cohort; adjunctive thiamine versus none, propensity-score matched (83 pairs); horizon is 30 days
- Dose studied
- not reported
In other words, patients who received thiamine as adjunctive therapy during ICU stay had a lower 30-day mortality rate by 63% [OR (95% CI): 0.37 (0.18, 0.78), P value = 0.009] (Table 1).”
Quoted verbatim from Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.cohortPermalink - Fasting blood glucoseMoved: no difference foundEffect, as reportedMD−0.2[−0.69 to 0.29]Evidence: ModeratePaper: PMID 360080642022
- Who
- Adults with type 2 diabetes; three pooled placebo-controlled trials; follow-up under 3 months
- Dose studied
- not reported
Pooled results from three trials demonstrated no statistically significant difference in the FBG level between those who received thiamine supplementation versus placebo after less than 3 months of follow-up (MD, −0.20 mmol/L; CI: −0.69 to 0.29).”
Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink - All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 288509302018
- Who
- Adults with septic shock and alcohol use disorder in an ICU (retrospective, unadjusted comparison); thiamine-treated patients versus patients given no thiamine; routes pooled (68% of initial doses parenteral, remainder oral)
- Dose studied
- most commonly 100 mg per dose
We found a significantly lower mortality for those receiving thiamine compared to those not receiving thiamine (15 [44%] vs. 15 [79%], p = 0.02, Table 2).”
Quoted verbatim from Thiamine in septic shock patients with alcohol use disorders: An observational pilot study.cohortPermalink - All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 418724382026
- Who
- Adult ICU patients with sepsis-associated delirium (Sepsis-3, MIMIC-IV, liver disease excluded); 332 received thiamine, 956 did not; crude unadjusted analysis, 30-day follow-up
- Dose studied
- not reported
In crude analysis, thiamine use was associated with a lower risk of 30-day mortality.”
Quoted verbatim from Association of thiamine supplementation with 30-day mortality among ICU patients with sepsis-associated delirium.cohort · 4 weeksPermalink - Glycated haemoglobin (HbA1c)Moved: no difference foundEffect, as reportedMD−0.02[−0.35 to 0.31]Evidence: ModeratePaper: PMID 360080642022
- Who
- Adults with type 2 diabetes; two pooled placebo-controlled trials; follow-up under 3 months
- Dose studied
- not reported
Two trials that investigated the effect of thiamine supplementation versus placebo on HbA1c levels demonstrated no statistically significant differences between the groups at less than 3-month follow-up period (mean difference, MD: −0.02%, 95% CI: −0.35 to 0.31).”
Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.8[0.67 to 0.94]Evidence: Moderatereplicated ×9Paper: PMID 396143572024
- Who
- Adult ICU patients with sepsis or septic shock at two Swiss university hospitals, 2012-2022; B1 group (n = 1054) versus control group on standard treatment without B1 or ascorbic acid (n = 2183); oral and intravenous thiamine pooled; all clusters combined; all-cause in-hospital mortality
- Dose studied
- not reported
Overall in-hospital mortality was not the same across the three treatment groups, with a lower mortality observed in patients in group B1 compared to the control group (hazard ratio 0.8, 95% confidence interval [0.67;0.94], p = 0.008, Fig. 1 and Supplementary Fig. 2).”
Quoted verbatim from Differential effects of thiamine and ascorbic acid in clusters of septic patients identified by latent variable analysis.cohortPermalink - All-cause mortalitycontestedMoved: lowersEvidence: Limitedreplicated ×9Paper: PMID 362594602023
- Who
- Adults with Sepsis-3 in the MIMIC-IV intensive care database, retrospective cohort; intravenous thiamine in ICU versus none; confounder-adjusted Cox model; horizon is ICU stay
- Dose studied
- not reported
In comparison with the TUR group, the TR group had a statistically significantly lower risk of ICU mortality.”
Quoted verbatim from Thiamine supplementation may be associated with improved prognosis in patients with sepsis.cohortPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.82[0.69 to 0.98]Evidence: Limitedreplicated ×9Paper: PMID 411847852025
- Who
- Critically ill patients with cerebrovascular disease in the MIMIC-IV database, propensity-score-matched thiamine users and non-users (1,585 matched pairs); 28-day all-cause mortality shown
- Dose studied
- not reported
With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53-0.89, P = 0.004), 14 days (HR = 0.78, 95%CI: 0.64-0.96, P = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69-0.98, P = 0.028) compared with non-thiamine use after adjustment.”
Quoted verbatim from Thiamine use and short-term prognosis in critical cerebrovascular disease: a propensity score matched retrospective analysis from the MIMIC-IV database.cohort · 4 weeksPermalink - All-cause mortalitycontestedMoved: lowersEvidence: Very limitedreplicated ×9Paper: PMID 422519132026
- Who
- Critically ill adults with sepsis-associated acute respiratory failure in the MIMIC-IV database; thiamine supplementation versus no thiamine, retrospective
- Dose studied
- not reported
Thiamine supplementation was independently associated with reduced in-hospital and ICU mortality in critically ill patients with sepsis-associated acute respiratory failure, particularly in the elderly.”
Quoted verbatim from The association between thiamine use and mortality in critically ill patients with sepsis-associated acute respiratory failure: A retrospective analysis of the MIMIC-IV database.cohortPermalink - Incidence of ICU deliriumMoved: lowersEffect, as reportedOR0.58[0.34 to 0.98]Evidence: Very limitedPaper: PMID 341185012021
- Who
- Critically ill patients; RCT-only subset of a meta-analysis that also pooled cohort studies, thiamine versus standard of care
- Dose studied
- not reported
In the analysis of RCTs, thiamine supplementation showed 42% lower odds of developing ICU delirium (OR 0.58, 95% CI, 0.34-0.98).”
Quoted verbatim from Effect of thiamine supplementation in critically ill patients: A systematic review and meta-analysis.meta-analysisPermalink - All-cause mortalitycontestedMoved: no difference foundEffect, as reportedOR0.87[0.62 to 1.21]Evidence: Very limitedreplicated ×1Paper: PMID 330368542020
- Who
- Patients with septic shock; pooled four randomized controlled trials of intravenous thiamine
- Dose studied
- not reported
Overall, compared with control group in patients with septic shock, intravenous thiamine revealed no substantial impact on mortality (odd ratio [OR] = 0.87; 95% confidence interval [CI) = 0.62 to 1.21; P = 0.40), lactate change (standard mean difference [SMD] = 0.04; 95% CI = -0.28 to 0.35; P = 0.82), Sequential Organ Failure Assessment (SOFA) change (SMD = 0.02; 95% CI = -0.18 to 0.21; P = 0.87), intensive care unit (ICU) stay (SMD = -0.02; 95% CI = -0.33 to 0.30; P = 0.90) or renal replacement therapy (OR = 0.47; 95% CI = 0.07 to 3.15; P = 0.43).”
Quoted verbatim from Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials.meta-analysisPermalink - Intensive care unit length of staycontestedMoved: raisesEffect, as reportedMD0.4[0.01 to 0.79]Evidence: Very limitedPaper: PMID 393070942024
- Who
- Critically ill patients; meta-analysis of randomized controlled trials of intravenous thiamine
- Dose studied
- not reported
Conversely, thiamine administration resulted in a slight increase in the length of ICU stay (MD, 0.40 days; 95% CI, 0.01-0.79 days; High CoE).”
Quoted verbatim from Effect of intravenous thiamine administration on critically ill patients: A systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.666[0.49 to 0.905]Evidence: Very limitedreplicated ×9Paper: PMID 300283622018
- Who
- Adults with septic shock admitted to medicine or surgery ICU; 123 thiamine-treated patients matched with 246 patients not receiving thiamine; retrospective single-center matched cohort
- Dose studied
- IV thiamine within 24 hours of hospital admission
Thiamine administration was also associated with a reduction in 28-day mortality (hazard ratio, 0.666; 95% CI, 0.490-0.905).”
Quoted verbatim from Effect of Thiamine Administration on Lactate Clearance and Mortality in Patients With Septic Shock.cohort · 4 weeksPermalink - All-cause mortalitycontestedMoved: no difference foundEvidence: Very limitedreplicated ×1Paper: PMID 326974832020
- Who
- Patients with septic shock requiring norepinephrine within 2 days of admission, Japanese nationwide database; thiamine 100 mg or more within 2 days of admission versus no thiamine, inverse probability of treatment weighting
- Dose studied
- 100 mg or 200 mg per day within 2 days of admission
The findings of this nationwide database-based observational study did not support an association between thiamine administration early after admission and the 28-day mortality in patients with septic shock.”
Quoted verbatim from Association Between IV Thiamine and Mortality in Patients With Septic Shock: A Nationwide Observational Study.cohort · 4 weeksPermalink - Intensive care unit length of staycontestedMoved: no difference foundEffect, as reportedSMD−0.02[−0.33 to 0.3]Evidence: Very limitedPaper: PMID 330368542020
- Who
- Patients with septic shock; pooled four randomized controlled trials of intravenous thiamine
- Dose studied
- not reported
Overall, compared with control group in patients with septic shock, intravenous thiamine revealed no substantial impact on mortality (odd ratio [OR] = 0.87; 95% confidence interval [CI) = 0.62 to 1.21; P = 0.40), lactate change (standard mean difference [SMD] = 0.04; 95% CI = -0.28 to 0.35; P = 0.82), Sequential Organ Failure Assessment (SOFA) change (SMD = 0.02; 95% CI = -0.18 to 0.21; P = 0.87), intensive care unit (ICU) stay (SMD = -0.02; 95% CI = -0.33 to 0.30; P = 0.90) or renal replacement therapy (OR = 0.47; 95% CI = 0.07 to 3.15; P = 0.43).”
Quoted verbatim from Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials.meta-analysisPermalink - Subjective fatigueMoved: lowersEvidence: Very limitedPaper: PMID 332102992021
- Who
- Patients with quiescent inflammatory bowel disease and severe chronic fatigue with no other explanation for it; placebo-controlled crossover, fatigue measured on the Inflammatory Bowel Disease-Fatigue Questionnaire
- Dose studied
- high-dose oral thiamine 600-1800 mg/d by gender and weight, 4 weeks
Crossover analysis showed a mean reduction of 4.5 points (95% CI 2.6-6.2) in fatigue after thiamine compared with a mean increase of 0.75 point (95% CI -1.3-2.8; P = 0.0003) after placebo.”
Quoted verbatim from Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.crossover · 4 weeksPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.046[0.002 to 0.86]Evidence: Very limitedreplicated ×9Paper: PMID 378804702024
- Who
- Infants (median age 4 months) admitted with acute non-infectious encephalopathy to a hospital in Sikkim; thiamine-treated versus untreated patients, retrospective
- Dose studied
- not reported
Thiamine treatment was significantly associated with reduced odds of mortality (aOR 0.046, 95% CI 0.0024-0.86, p 0.039).”
Quoted verbatim from Thiamine Responsive Acute Infantile Encephalopathy.cohortPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.58[0.45 to 0.74]Evidence: Very limitedreplicated ×9Paper: PMID 343928482022
- Who
- Critically ill adults with acute kidney injury in the MIMIC III database, propensity-score matched; early thiamine (within 48 h of ICU admission) versus none; 90-day horizon
- Dose studied
- not reported
Early thiamine use was associated with lower in-hospital mortality (OR 0·65; 95 % CI 0·49, 0·87; P < 0·001) and 90-d mortality (OR 0·58; 95 % CI 0·45, 0·74; P < 0·001), and it was also associated with the recovery of renal function (OR 1·26; 95 % CI 1·17, 1·36; P < 0·001).”
Quoted verbatim from Associations between early thiamine administration and clinical outcomes in critically ill patients with acute kidney injury.cohort · 3 monthsPermalink
No row matches these filters.
No dose is advised.